Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics, Inc. (NASDAQ: ANGO) is a medical technology company whose news flow centers on vascular interventions, oncology technologies, and corporate developments. Company announcements emphasize its focus on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients.
News releases frequently highlight performance across AngioDynamics’ two main platforms, Med Tech and Med Device. Investors can follow updates on Med Tech growth, including results from the Auryon peripheral atherectomy platform, the Mechanical Thrombectomy business (AngioVac and AlphaVac), and the NanoKnife irreversible electroporation platform. Earnings reports describe trends in Med Tech and Med Device net sales, gross margin, and the use of non‑GAAP measures such as adjusted EBITDA and pro forma results.
AngioDynamics also issues news about regulatory milestones and clinical studies. Recent items include FDA IDE approvals for the APEX‑Return study evaluating the AlphaReturn Blood Management System with AlphaVac F1885 in acute pulmonary embolism, and the PAVE clinical study assessing the AngioVac System for right‑sided infective endocarditis. The company has reported FDA 510(k) clearance for a modified AlphaVac F1885 System with expanded indications, as well as publication of the PRESERVE study of the NanoKnife System for prostate tissue ablation in European Urology.
Additional news topics include recognition of the NanoKnife System on TIME’s 2025 Best Inventions list, enrollment milestones in trials such as AMBITION BTK and RECOVER‑AV, participation in investor conferences, and scheduling of quarterly earnings calls. For investors and observers, the ANGO news stream offers insight into product performance, clinical evidence, regulatory progress, and the company’s strategic focus on Med Tech growth.
AngioDynamics (NASDAQ: ANGO) reported financial results for Q1 FY2025, ending August 31, 2024. Net sales reached $67.5 million, a 1.1% increase year-over-year. Med Tech sales grew 8.7% to $28.0 million, while Med Device sales decreased 3.6% to $39.5 million. The company reported a GAAP loss per share of $0.31 and an adjusted loss per share of $0.11.
Key highlights include:
- Submission for FDA 510(k) clearance for NanoKnife's Prostate Tissue indication
- CE Mark Approval in Europe for the Auryon System
- Initiation of RECOVER-AV Clinical Trial in Europe for AlphaVac
For FY2025, AngioDynamics expects net sales between $282-$288 million, representing 4.2%-6.4% growth over FY2024 pro forma revenue. The company anticipates an adjusted EBITDA loss of $2.5 million to $0 and an adjusted loss per share of $0.38 to $0.42.
AngioDynamics, Inc. (NASDAQ: ANGO) has launched the RECOVER-AV clinical trial to evaluate the AlphaVac F18⁸⁵ System for treating acute, intermediate-risk pulmonary embolism (PE) in the European market. This multi-center, multi-national study follows the successful APEX-AV trial in the US, which showed significant improvements in right ventricular function and clot burden reduction.
The RECOVER-AV trial will enroll patients across up to 20 European hospital sites, focusing on the reduction of the right ventricular/left ventricular ratio and major adverse events. Patients will be followed for 12 months to assess functional outcomes. This study is significant given the higher prevalence and acuity of PE in Europe compared to the US.
The AlphaVac F18⁸⁵ System recently received CE Mark approval in Europe for non-surgical removal of thrombi or emboli from pulmonary arteries. The trial is led by renowned experts in vascular medicine and cardiology, supported by an international Scientific Advisory Board.
AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment, has announced its plans to release fiscal 2025 first quarter financial results on October 3, 2024, before the market opens. The company will host a conference call at 8:00 am ET on the same day to discuss the results. Investors can participate by dialing 1-877-407-0784 (domestic) or +1-201-689-8560 (international). A webcast will be available on the company's website, and a recording of the call can be accessed until October 10, 2024, using the passcode 13748896.
AngioDynamics (NASDAQ: ANGO) has received European CE Mark approval for its Auryon Atherectomy System, a revolutionary solid-state laser technology for treating Peripheral Artery Disease (PAD). This approval enables the company to enter the European market, expanding its reach in the global PAD market valued at $1.1 billion.
The Auryon System, which received FDA clearance in 2020, has already treated over 50,000 patients in the US. Clinical studies have shown its effectiveness in treating various lesion types with minimal vessel wall impact. The system uses a 355nm wavelength laser platform, allowing for targeted biological reactions without thermal ablation.
Recent studies, including the PATHFINDER registry, have demonstrated the system's safety and efficacy in treating complex PAD cases, showing significant improvements in patient outcomes.
AngioDynamics, Inc. (NASDAQ: ANGO), a leading medical technology company focused on vascular health and cancer treatment, has announced its participation in two upcoming investor conferences. The company will attend the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 12, 2024, and present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, at 10:00 am.
Investors can access a live webcast of the Canaccord Genuity presentation through the 'Investors' section of AngioDynamics' website. These conferences provide an opportunity for the company to showcase its innovative medical technologies and engage with potential investors.
AngioDynamics reported its fiscal year 2024 Q4 and full-year results, showing pro forma net sales of $71.1 million for Q4 (1.9% YoY growth) and $270.7 million for FY2024 (5.3% YoY growth). The company's Med Tech segment saw strong growth, with Q4 sales up 11.3% YoY to $29.3 million. However, AngioDynamics reported a GAAP net loss of $13.4 million in Q4 and $184.3 million for the full year.
Key highlights include FDA clearance and CE Mark approval for the AlphaVac F18 System for pulmonary embolism treatment, a $15 million share repurchase program, and the completion of several strategic divestitures. The company also initiated a transition to a fully outsourced manufacturing model to drive efficiencies and cost savings.
For fiscal year 2025, AngioDynamics expects net sales between $282-$288 million, representing 4.2-6.4% growth over FY2024.
AngioDynamics, a medical technology company, will report its fiscal 2024 fourth-quarter and full-year financial results on July 16, 2024, before market open. The company focuses on restoring blood flow in the vascular system, expanding cancer treatments, and improving patient quality of life. A conference call to discuss the results will be held at 8:00 a.m. ET on the same day. Dial-in options are available for both domestic and international participants, and the call will be webcast on the AngioDynamics investor website. A replay will be accessible online and via phone until July 23, 2024.
AngioDynamics (NASDAQ: ANGO) has received CE Mark approval in Europe for its AlphaVac F1885 System. This regulatory milestone allows the company to market the mechanical thrombectomy system for non-surgical removal of thrombi or emboli from the pulmonary arteries, aiding in the treatment of pulmonary embolism (PE). The system aims to improve patient outcomes in the EU, where PE has a higher prevalence compared to the U.S. In December 2023, AngioDynamics completed patient enrollment for its U.S.-based APEX-AV trial, which showed significant decreases in RV/LV ratios and clot burdens, with a low Major Adverse Event rate.
AngioDynamics, Inc. presented results from the APEX-AV trial assessing the AlphaVac F1885 System for pulmonary embolism treatment at SCAI 2024 Scientific Sessions. The trial showed significant improvement in right ventricular function, clot burden reduction, and low Major Adverse Event rate. The FDA clearance of the device marks a milestone in interventional medicine.
Summary not available.